During the inflammatory response, the adhesion molecule PECAM plays a crucial role in transendothehal migration, the passage of leukocytes across endothelium. We report here an additional role for PECAM in the subsequent migration of monocytes through the subendothelial extraceHular matrix. PECAM has six immunoglobulin (Ig) superfamily domains. Monoclonal antibodies whose epitopes map to domains 1 and/or 2 selectively block monocyte migration through the endothelial junction, whereas those that map to domain 6 block only the migration through the extracellular matrix, trapping the monocyte between the endothelium and its basal lamina. Therefore, transendothelial migration (diapedesis) and passage through extracellnlar matrix (interstitial migration) are distinct and separable phases of monocyte emigration. Furthermore, distinct and separate Ig domains of PECAM are involved in mediating these two steps.
D
uring the final stages of emigration from the bloodstream into a site of inflammation, white blood cells, or leukocytes, squeeze between tightly apposed endothelial cells (EC) 1 of the vascular wall without disrupting vascular permeability. This transendothehal migration (TEM) involves platelet/endothelial cell adhesion molecule-1 (PECAM, CD31), which is expressed on the surfaces of leukocytes and concentrated along the borders between ECs (1, 2). PECAM is composed of six extracellular immunoglobulin domains (2) . A homophilic interaction (i.e., an interaction between neutrophil or monocyte PECAM and endothelial PECAM) is required for TEM. When antibody to PECAM is applied to either the leukocyte or endothelium, TEM is blocked both in vitro and in vivo (3) (4) (5) (6) . Less is known about the subsequent migration of leukocytes through the endothelial basal lamina and the interstitial matrix. Using quantitative in vitro assays that dissect different steps in leukocyte transit, we now demonstrate an additional role for PECAM just after the leukocyte has crossed the endothelial junction. This role is mediated by a domain of PECAM distinct from those involved in transendothelial migration and appears to involve heterophilic interactions 1Abbreviations used in this paper: EC, endothelial cells; HUVEC, human umbilical vein endothelial cells; Mo, monocytes; N-CAM, neural cell adhesion molecule; Ng-CAM, neuron-glial cell adhesion molecule; PECAM, platelet/endothelial cell adhesion molecule-I; TEM, transendothelial migration.
of leukocyte PECAM with components of the extracellular matrix.
Materials and Methods

Construction of Truncated PECAM-IgG Chimeric Proteins.
A fulllength PECAM-IgG cDNA was constructed by interrupting PECAM cDNA at the putative membrane insertion site with a NotI site and ligating with a cDNA encoding the hinge and CH2 and CH3 regions of human IgG1 (generously provided by Drs. Mickey Hu and Mark Zukowski of Amgen, Inc. Thousand Oaks, CA), and subsequently subcloned into the expression vector pcD-NAI/Neo (Invitrogen, San Diego, CA). PC1K technology was used to produce a series of PECAM constructs differing by the addition of a complete 3' domain. A common 5' primer and a series of 3' primers engineered with HindlII and NotI sites, respectively, were used to amplify DNA encoding only the desired segments of PECAM (2, 7). These were then ligated into pcDNAI/ Neo and rejoined with hlgG in a separate step. The sequence of the 5' primer was 5'-TCAG TAGACCACCATG-CAG-3'. The shaded area represents the HindlII site. The initiator ATG codon is underlined. The sequences of the 3' primers were;
The shaded areas mark the NotI restriction site. Human Umbilical Vein Endothelial Cell Culture, Leukocyte Isolation, and Transendothelial Migration Assays. These were all performed as described in detail in references l, 10, and 3, respectively. Briefly, human umbilical vein endothelial cells (HUVEC) were grown to confluence on hydrated Type I collagen gels in the presence of 20% normal human serum without additional growth factors. Peripheral blood mononuclear cells were added to the medium above these monolayers and monocyte-selective transendothelial migration (10) was allowed to proceed for 1 or 2 hours in the presence of anti-PECAM reagents or controls. The monolayers were then treated as described (3) . Monocytes arrested on the apical surface were identified by their ability to bind hl0d; Only mAb binding to PECAM domains 1 and/or 2 block TEM ofMo. PBMC were incubated with the indicated mAb at 20 I~g/ml, or heparin or dextran sulfate (Sigma Chemical Co., St. Louis, MO) at 50 ~g/ml and added to HEC monolayers for 2 h at 37~ (concentrations previously found to block optimally [3, 14] ). The monolayers were washed with EGTA to remove unbound and integrin-bound leukocytes. The percent of cells remaining associated with the HEC that had transmigrated below the monolayer was quantitated as described (3) . Approximately 100 cells were counted for each replicate monolayer. The bars represent the mean and standard error for six replicate monolayers. In cases where two m.Ab were added, the concentration of each was 20 ~g/ml. W6/32 is a mAb against Class I MHC antigen used as a negative control (3). PECAM-IgG is the full-length PECAMIgG chimera containing domains 1-6. Two independent experiments are shown as a and b.
IgG-or C3bi-coated sheep erythrocytes. Transmigrated monocytes were at a lower focal plane and did not bind opsonized erythrocytes (3).
Interstitial Migration Assay. To quantitate migration into the gel, the fixed, Wright/Giemsa stained monolayers were examined by Nomarski optics at 400• The microscope was focused on the apical surface of the monolayer. The fine focus was then moved slowly through serial increments of 5 Ixm and the number of monocytes (Mo) within that level were scored.
Electron Microscopy. Electron microscopy was performed by standard techniques essentially as described (1) . Monolayers of HUVEC on collagen were fixed in half-strength Karnovsky's fixative and postfixed with osmium tetroxide prior to embedding in Epon. Cross-sections of the monolayer were cut on a ReichertJung ultramicrotome and viewed on an electron microscope (JEOL 100 CX-II, JEOL U.S.A. Inc., Peabody, MA).
Results and Discussion
A n t i -P E C A M monoclonal antibody (mAb) hec7 blocks T E M of M o and neutrophils (PMN) in a quantitative in vitro assay (3). The block is selective for TEM. There is no diminution of the ability of the leukocytes to adhere to the apical surface o f the ECs; rather, the leukocytes remain tightly adherent over the intercellular borders, reversibly arrested in their transendothelial passage (3) . N o t all anti-P E C A M mAb block TEM; functional studies in conjunction with mAb mapping were used to determine which extracellular domains of P E C A M are critical for TEM.
The extracellular portion of P E C A M is organized into six Ig domains (2) . A series of sequentially truncated P E C A MIgG chimeras were synthesized in order to map the epitopes of a panel of mAb (Fig. 1 a) . The truncated P E C A M -I g G chimeras ran at the expected molecular mass on nonreduced SDS-PAGE (Fig. 1 b) . In an ELISA the mAb P1.3 bound to all of the constructs containing domain 1, including the shortest containing only domain 1 (Fig. 1 c) . Binding of hec7 and L133.1 required expression of both domains 1 and 2. PI.1 bound only to the constructs containing domain 5, whereas the mAbs P1.2 and 4G6 bound only to full-length constructs containing domain 6 (Fig. 1 c) . W e will refer to hec7 and L133.1 as domain 1 and/or 2 mAb and P1.2 and 4G6 as domain 6 mAb, although these constructs alone cannot assign the domain o f the epitope unambiguously. Nevertheless, our results are consistent with a recently published study in which a different technique was used to identify the epitopes of a n t i -P E C A M mAb (11) .
All mAb used in these experiments bind to M o equivalently. However, only the three mAb that bound to P E C A M domain 1 and/or 2 blocked T E M in our in vitro assay (Fig.  2) . In a representative experiment hec7, L133.1, and P l . 3 blocked T E M of M o by 73, 67, and 70%, respectively, whereas mAb P1.1, P1.2, and 4G6 had no effect (Fig. 2) . Under the conditions used in these experiments, the mAb exerts its effect by binding to monocyte P E C A M rather than the endothelial P E C A M (3).
O u r assay employs direct visualization of the interacting cells to assess the final positions of Mo in relation to the endothelial monolayer. M o treated with anti-PECAM mAb that recognized domain 6 migrated across the endothelial monolayer. Once under the monolayer, however, they remained close to the abluminal surface of the endothelium instead of migrating deep into the collagen gels, as M o treated with control mAb. .2 a n d h e c 7 did n o t c h a n g e the ability o f hec7 to block T E M (Fig. 2 b) , n o r did it alter the ability o f P1.2 to b l o c k m i g r a t i o n o f M o into the collagen gel (Fig. 3 b) . , or heparin were seen in the superficial portion of that level, immediately beneath the EC. Data using anti-domain 6 mAb or heparin are shown in black bars; data using other reagents are shown in shaded bars. The data are expressed as the percentage of total cells below the HEC monolayer that were seen at each level. The mean and standard errors for six replicate samples are given for part b; for part a the mean of six replicate samples is given, the standard errors were all less than 10% of the mean value. >100 cells were counted for each of six replicate monolayers for each sample, thus, more fields were counted for hec7-, P1.3-, and L133.1-treated samples.
A n e x p e r i m e n t identical to that o f Fig. 3 was p e r f o r m e d , b u t this time cultures w e r e fixed a n d e m b e d d e d in E p o n . D e p t h o f M o m i g r a t i o n was q u a n t i t a t e d in 1-~,m sections cut p e r p e n d i c u l a r to the endothelial m o n o l a y e r , a n d similar results w e r e o b t a i n e d (not shown). This material was t h e n e x a m i n e d by electron microscopy. M a n y o f the cells treated w i t h a n t i -d o m a i n 6 m A b w e r e retained b e t w e e n the basal surface o f the E C a n d the basal lamina (Fig. 4, b a n d c) . In contrast, mAb hec7 blocked T E M at the apical surface of the EC (Fig. 4 a) , as previously demonstrated (3) .
As previously mentioned, PECAM on a leukocyte can bind in a homophilic manner to PECAM on the EC (3), but PECAM-transfected L cells can also aggregate in a PECAMdependent heterophilic manner (12) (13) (14) (15) . Heparan sulfate proteoglycans are ligands for this heterophilic adhesion. However, to date there has been no known physiologic function for the binding of PECAM to proteoglycan. It was apparent that the ability of mAb to inhibit interstitial migration exactly paralleled their ability to inhibit heterophilic aggregation of PECAM-transfected L cells. In those published experiments, P1.2 and 4G6 inhibited, but hec7, L133.1, P1.1 and P1.3 were inactive (15) (and unpublished results). Heparin at 50 p~g/ml (and heparan sulfate, not shown), which blocked heterophilic aggregation (14, 15) similarly inhibited migration through extracellular matrix (Fig. 3 ). This was a specific effect of heparin, since dextran sulfate, a similarly charged polymer used at the same concentration, had no effect. Neither polymer had a significant effect on TEM (Fig. 2) . The site(s) on PECAM that interact with heparin have not been defined. Conversely, fulllength PECAM-IgG, which would be expected to interact homophilically with PECAM on Mo blocked TEM (Fig. 2  a) but had no effect on interstitial migration (Fig. 3 a) .
We conclude that while the homophilic interaction of the amino-terminal region of leukocyte PECAM with PECAM of the EC is involved in transendothelial migration per se, heterophilic interaction of the membrane-proximal region of leukocyte PECAM with heparan sulfate proteoglycans (such as perlecan) in the endothelial basal lamina, and possibly deeper in the interstitial tissues, is involved in the movement of transmigrated leukocytes through the extracellular matrix. A schematic diagram of the PECAM molecule with its mAb epitopes and putative functional domains is shown in Fig. 5 . Whether interaction with proteoglycans serves this function by promoting adhesion directly, via activating leukocyte integrins (9, 16, 17) , or by stimulating monocyte secretion of matrix-degrading proteases is under investigation.
Only two other adhesion molecules, neuron-glial cell adhesion molecule (Ng-CAM) (18) and neural cell adhesion molecule (N-CAM) exhibit both homophilic and heterophilic binding functions. N -C A M binds to itself via domain 3 (19) and to heparin via domain 2 (20) . The domains responsible for the adhesive interactions of N g -C A M with itself (18) or the heterophilic ligands laminin (21) and chondroitin sulfate proteoglycans (22, 23) have not been identified. The leukocyte integrin VLA-4 (c~4131) has been shown to bind heterophilically to two different ligands, the endothelial cell adhesion molecule VCAM-1 and the matrix molecule fibronectin via two separate domains (24) . The endothelial adhesion molecule MAdCAM-1 supports rolling interactions with lymphocyte o~4~ 7 (25) as well as L-selectin (26), presumably via Ig-like and mucin-like domains, respectively. However, the present report is the first description of a leukocyte-endothelial cell adhesion molecule that utilizes distinct domains for two different mechanisms of interaction (homophilic and heterophilic), to mediate two separate and sequential functions, transendothelial migration and migration through extracellular matrix, respectively.
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